ADEWALE OYEMADE: Open Payments
NPI 1801054366 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,026 in 46 payments from 13 companies in 2025. Trend: 2023 $1,138 · 2024 $876 · 2025 $1,026
Food & beverage: $987Education: $39
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $139 |
| Corium, LLC | 6 | $115 |
| Supernus Pharmaceuticals, Inc. | 3 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $110 |
| Noven Therapeutics, LLC | 5 | $93 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Tris Pharma Inc | 4 | $78 |
| Lundbeck LLC | 1 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
Products named: REXULTI, CAPLYTA, Azstarys, Qelbree, TRINTELLIX, Xelstrym, Auvelity, Onyda XR.
Industry payments across LA — which companies pay providers there.
